VOR: Reporting persons disclose open-market sales and 21.9% ownership

Rhea-AI Filing Summary

Amendment No. 5 to a Schedule 13D reports that Reprogrammed Interchange LLC and Reid Hoffman collectively beneficially own 1,498,921 shares of Vor Biopharma Inc., representing 21.9% of the outstanding common stock. The amendment discloses open-market sales that reduced the Reporting Persons' stake by more than one percent: 70,763 shares sold on 10/06/2025 at a weighted average price of $37.0079 and 27,624 shares sold on 10/07/2025 at $33.8369. The filing also lists multiple earlier sales between 08/25/2025 and 10/03/2025 with individual weighted average prices, and states no new arrangements, contracts, or legal proceedings.

Positive

• Detailed disclosure of share counts and weighted average prices for each sale
• Current stake retained at 1,498,921 shares representing 21.9%

Negative

• Large open-market sales totaling >98,000 shares on 10/06/2025-10/07/2025
• Weighted average sale prices declined from $37.0079 to $33.8369 over two days

Insights

Equity Ownership Analyst

Holder disclosed sustained open-market sales leaving a 21.9% stake.

The filing shows the Reporting Persons currently hold 1,498,921 shares (21.9%) after multiple open-market disposals, including sales on 10/06/2025 and 10/07/2025. The pattern is documented with specific share counts and weighted average prices, which clarifies their public stake and voting/dispositive arrangements.

Key dependencies include ongoing open-market activity and public float changes; monitor subsequent Schedule 13D/X filings for further stake shifts over the next few trading sessions.

Market Microstructure Specialist

Sales occurred at falling weighted average prices across disclosed dates.

Reported weighted average sale prices decline across the October transactions from $37.0079 to $33.8369, and earlier September trades show a downward trend into mid-September. This detail signals timing and execution in open-market conditions rather than block transfers.

The immediate risk is continued selling pressure if disposals persist; watch intraday volume and subsequent 13D amendments over the next week for execution pace and price impact.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

VOR BIOPHARMA INC.

(Name of Issuer)

Common Stock, par value $.0001 per share

(Title of Class of Securities)

929033108

(CUSIP Number)

Frank Huang, Manager
101 Mission Street, Suite 1000,
San Francisco, CA, 94105
(415) 541-0200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/06/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 929033108

1

Name of reporting person

Reprogrammed Interchange LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,498,921.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,498,921.00

11

Aggregate amount beneficially owned by each reporting person

1,498,921.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

21.9 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 929033108

1

Name of reporting person

Reid Hoffman

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,498,921.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,498,921.00

11

Aggregate amount beneficially owned by each reporting person

1,498,921.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

21.9 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $.0001 per share
(b)	Name of Issuer: VOR BIOPHARMA INC.
(c)	Address of Issuer's Principal Executive Offices: 100 Cambridgepark Drive, Suite 101, Cambridge, MASSACHUSETTS , 02140.
Item 1 Comment: This Amendment No. 5 to Schedule 13D amends and supplements the information provided in the previously filed Statement on Schedule 13D filed with the Securities and Exchange Commission on January 7, 2025 and in Amendment No. 1, Amendment No. 2, Amendment No. 3 and Amendment No. 4 thereto filed with the Securities and Exchange Commission on August 29, 2025, September 9, 2025, September 12, 2025 and October 6, 2025, respectively (collectively, the "Schedule 13D"), jointly on behalf of Reprogrammed Interchange LLC and Reid Hoffman (each a "Reporting Person" and collectively, the "Reporting Persons"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain unchanged in all material respects and in full force and effect. Capitalized terms used but not defined herein have the meaning ascribed to such term in the Schedule 13D, as amended. Responses to each item of this Amendment No. 5 to Schedule 13D are incorporated by reference into the response to each other item, as applicable.
Item 3.	Source and Amount of Funds or Other Consideration
	Not applicable.
Item 4.	Purpose of Transaction
	Item 4 of Schedule 13D is hereby amended and supplemented as follows: From October 6, 2025 through October 7, 2025, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions, resulting in a decrease in the number of shares of Common Stock beneficially owned by the Reporting Persons by more than one percent of the outstanding shares of Common Stock of the Issuer. 1. 70,763 shares on October 6, 2025, at a weighted average per share sale price of $37.0079. 2. 27,624 shares on October 7, 2025, at a weighted average per share sale price of $33.8369.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Amendment No. 5 to the Schedule 13D, and the information set forth or incorporated in Items 2, 3, 4, 6 and 7, is incorporated by reference in its entirety into this Item 5.
(b)	Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets, (ii) shared power to vote or to direct the vote: See line 8 of cover sheets, (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets, and (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
(c)	During the past 60 days, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions. Each share amount and weighted average per share sale price from August 25, 2005 through September 16, 2025 reflects the 1-for-20 reverse stock split of Vor Biopharma Inc. Common Stock effected September 18, 2025. 1. 19,367 shares on August 25, 2025, at a weighted average per share sale price of $42,3256. 2. 14,209 shares on August 26, 2025, at a weighted average per share sale price of $41.6165. 3. 30,582 shares on August 27, 2025, at a weighted average per share sale price of $40.1057. 4. 40,317 shares on August 28, 2025, at a weighted average per share sale price of $40.2307. 5. 27,730 shares on September 3, 2025, at a weighted average per share sale price of $39.9222. 6. 22,650 shares on September 4, 2025, at a weighted average per share sale price of $38.5709. 7. 20,000 shares on September 5, 2025, at a weighted average per share sale price of $39.3639. 8. 23,221 shares on September 8, 2025, at a weighted average per share sale price of $39.7949. 9. 22,461 shares on September 9, 2025, at a weighted average per share sale price of $40,0084. 10. 17,500 shares on September 10, 2025, at a weighted average per share sale price of $36.3019. 11. 14,240 shares on September 11, 2025, at a weighted average per share sale price of $36.6151. 12. 15,000 shares on September 12, 2025, at a weighted average per share sale price of $35.0811. 13. 20,000 shares on September 15, 2025, at a weighted average per share sale price of $32.815. 14. 22,363 shares on September 16, 2025, at a weighted average per share sale price of $30.8023. 15. 1,400 shares on October 1, 2025, at a weighted average per share sale price of $39.1925. 16. 32,451 shares on October 2, 2025, at a weighted average per share sale price of $39.828. 17. 7,901 shares on October 3, 2025, at a weighted average per share sale price of $37.832.
(d)	Not applicable.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Reprogrammed Interchange LLC

Signature:	/s/ Frank Huang
Name/Title:	Frank Huang, Manager
Date:	10/08/2025

Reid Hoffman

Signature:	/s/ Reid Hoffman
Name/Title:	Reid Hoffman
Date:	10/08/2025

FAQ

How many Vor Biopharma (VOR) shares do the Reporting Persons now own?

They beneficially own 1,498,921 shares, representing 21.9% of VOR common stock.

What shares were sold by Reprogrammed Interchange LLC on 10/06/2025 and 10/07/2025?

They sold 70,763 shares on 10/06/2025 at a weighted average of $37.0079 and 27,624 shares on 10/07/2025 at $33.8369.

Does the filing report any contracts or arrangements related to VOR securities?

No. Item 6 states Not applicable, indicating no new contracts or arrangements were disclosed.

Are there legal proceedings disclosed that affect the Reporting Persons' holdings?

No. The cover pages indicate no disclosure of legal proceedings is required for Items 2(d) or 2(e).

Were earlier sales disclosed in the filing for the past 60 days?

Yes. The filing lists multiple sales between 08/25/2025 and 10/03/2025 with specific share counts and weighted average prices.